Form 4: Supernus Pharmaceuticals Director Exercises Stock Options

Frederick M. Hudson, a director at Supernus Pharmaceuticals, exercised stock options and acquired 20,000 shares of common stock on January 22, 2025.

Summary

• On January 22, 2025, Frederick M. Hudson, a director of Supernus Pharmaceuticals, exercised stock options.
• This transaction resulted in the acquisition of 20,000 shares of common stock at a price of $9.13 per share.
• Following the transaction, Hudson directly owns 48,395 shares of Supernus Pharmaceuticals common stock.
• The stock options were granted on March 3, 2016, and were exercisable until March 3, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director exercising stock options, which is neither inherently positive nor negative.

Positives

• The exercise of stock options by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's activity in the company's stock.

Comparison to Industry Standards

• Director stock option exercises are common in the pharmaceutical industry as a form of executive compensation.
• Comparing the exercise price and the number of shares acquired to similar transactions at comparable companies like Teva or Mylan would provide further context.

Stakeholder Impact

• The transaction has a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates